<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424473</url>
  </required_header>
  <id_info>
    <org_study_id>ONT-380-014</org_study_id>
    <nct_id>NCT03424473</nct_id>
  </id_info>
  <brief_title>Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <brief_summary>
    <textblock>
      Physicians interested in requesting a single patient IND should contact Seattle Genetics'
      Medical Information (medinfo@seagen.com).
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tucatinib</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>ARRY-380</keyword>
  <keyword>ONT-380</keyword>
  <keyword>HER2 Positive Breast Carcinoma</keyword>
  <keyword>HER2 Positive Locally Advanced Breast Cancer</keyword>
  <keyword>HER-2 Positive Breast Cancer</keyword>
  <keyword>HER-2 Positive Locally Advanced Breast Cancer</keyword>
  <keyword>Recurrent Breast Carcinoma</keyword>
  <keyword>Stage IV Breast Cancer</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Metastatic Malignant Neoplasm in the Brain</keyword>
  <keyword>Brain Metastases in Breast Cancer</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Breast Diseases</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

